Text of the NIH Decision.

Statement of Essential Inventions in Response to the Decision

Statement of Jerome H. Reichman on March-In Rights Under the Bayh-Dole Act.

March 10, 2004. LETTER TO THE DIRECTOR OF THE OFFICE OF TECHNOLOGY TRANSFER, NIH, REQUESTING A HEARING ON ESSENTIAL INVENTIONS' MARCH-IN REQUESTS.

January 29, 2004. PETITION TO USE AUTHORITY UNDER BAYH-DOLE ACT TO PROMOTE ACCESS TO LATANOPROST, SUPPORTED BY U.S. PUBLIC HEALTH SERVICE RESEARCH GRANT NUMBERS EY 00333 AND EY 00402 FROM THE NATIONAL EYE INSTITUTE, DEPARTMENT OF HEALTH AND HUMAN SERVICES

Letter from Mark L. Rohrbaugh, Director of the NIH Office of Technology Transfer to James Love and Sean Flynn, informing Essential Inventions that NIH is close to a decision.

February 12, 2004, DHHS Secretary Thompson assigns NIH to review March-In Requests on Xalatan and Norvir

Text of the Bayh-Dole Act.

Federal Regulations on Procedure Governing the March-In Right Under the Bayh-Dole Act.

March 30, 2004. Letter from Mike Naylor, AARP Director of Advocacy, to DHHS Secretary Tommy Thompson in Support of March-In Effort.

March 25, 2004. Letter from 15 Patient Groups Tommy Thompson in Support of March-In Effort.

March 30, 2004. Joint release from the AIDS Treatment Activists Coalition and the Consumer Project on Technology. Pressure Mounts for U.S. to Open Competition on Two Government Funded Medicines.

January 29, 2004, March-in press release on Norvir and Xalatan

January 29, 2004, March-in backgrounder

Government funding for Xalatan